← Leaderboards
Mark Thomas Gladwin
Clinical Center
$38,765,597
Attributed
$51,971,784
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.9M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$75,323,142 · 15
By mechanism
P01$29,966,552 · 5
R01$21,168,928 · 4
UH3$16,082,959 · 1
T32$4,192,321 · 2
UG3$1,459,550 · 1
P30$1,453,652 · 1
Top collaborators
- Daniel B Kim-Shapiro15 shared
- Jesus Tejero Bravo6 shared
- Tamir Kanias4 shared
- Sruti Shiva4 shared
- Darrell J Triulzi4 shared
- Paola Corti3 shared
- Bruce A Freeman2 shared
Most similar at Clinical Center
Same institution · by research overlap
Others in their field
Top investigators on “Nitric Oxide”
- Solomon H Snyder · Johns Hopkins University$33,003,131
- Jay Louis Zweier · Ohio State University$27,671,715
- Stuart A Lipton · Burnham Institute For Medical Research$26,301,120
- Serpil C. Erzurum · Cleveland Clinic Lerner Com-Cwru$24,661,240
- Jonathan S. Stamler · Case Western Reserve University$24,571,968
- William C. Sessa · Yale University$21,022,028
Research focus
Nitric OxideBlood VesselsLungHemoglobinErythrocytesSickle Cell AnemiaIn VivoSignal TransductionNitritesCellsBaseClinical TrialsBloodSafetyPathway InteractionsPhysiologicalIn VitroFunctional DisorderHemolysisProgramsReactionAcuteMouse ModelProtocols Documentation
Grant awards (145)
Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE$1,171,075
UH3 · FY2025 · HL · contact PI
Omics, mice and men: Development of precision transfusion medicine$765,351
R01 · FY2025 · HL · contact PI
Airway epithelial cytoglobin regulates nitric oxide synthase and development of primary ciliary dyskinesia and situs inversus$697,617
R01 · FY2025 · HL · contact PI
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin$676,342
R01 · FY2025 · HL · contact PI
Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE$2,550,443
UH3 · FY2024 · HL · contact PI
Omics, mice and men: Development of precision transfusion medicine$750,647
R01 · FY2024 · HL · contact PI
Airway epithelial cytoglobin regulates nitric oxide synthase and development of primary ciliary dyskinesia and situs inversus$724,867
R01 · FY2024 · HL · contact PI
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin$660,807
R01 · FY2024 · HL · contact PI
Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE$3,349,999
UH3 · FY2023 · HL · contact PI
Omics, mice and men: Development of precision transfusion medicine$825,222
R01 · FY2023 · HL · contact PI
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin$703,592
R01 · FY2023 · HL · contact PI
Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE$2,667,908
UH3 · FY2022 · HL · contact PI
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)$680,622
UH3 · FY2022 · HL · contact PI
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)$2,887,088
UH3 · FY2021 · HL · contact PI
Omics, mice, and men: Development of precision transfusion medicine$758,633
R01 · FY2021 · HL
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin$708,733
R01 · FY2021 · HL · contact PI
Training in Translational Research and Entrepreneurship in Pulmonary Vascular Biology$207,136
T32 · FY2021 · HL · contact PI
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)$2,775,824
UH3 · FY2020 · HL · contact PI
Omics, mice, and men: Development of precision transfusion medicine$759,318
R01 · FY2020 · HL · contact PI
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin$708,733
R01 · FY2020 · HL · contact PI
Nitrite-signaling to modulate the metabolic syndrome and PH in patients with PH-HFpEF$630,438
P01 · FY2020 · HL · contact PI
Training in Translational Research and Entrepreneurship in Pulmonary Vascular Biology$550,298
T32 · FY2020 · HL · contact PI
Administrative Core$156,501
P01 · FY2020 · HL · contact PI
Therapeutic Targeting of Vascular Subphenotypes of Lung Disease$2,713,014
P01 · FY2019 · HL · contact PI
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)$1,459,550
UG3 · FY2019 · HL · contact PI
Omics, mice, and men: Development of precision transfusion medicine$759,990
R01 · FY2019 · HL · contact PI
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin$722,858
R01 · FY2019 · HL · contact PI
Nitrite-signaling to modulate the metabolic syndrome and PH in patients with PH-HFpEF$630,438
P01 · FY2019 · HL · contact PI
Training in Translational Research and Entrepreneurship in Pulmonary Vascular Biology$420,322
T32 · FY2019 · HL · contact PI
Administrative Core$156,500
P01 · FY2019 · HL · contact PI
Therapeutic Targeting of Vascular Subphenotypes of Lung Disease$2,714,385
P01 · FY2018 · HL · contact PI
Omics, mice, and men: Development of precision transfusion medicine$788,194
R01 · FY2018 · HL · contact PI
Nitrite-signaling to modulate the metabolic syndrome and PH in patients with PH-HFpEF$630,438
P01 · FY2018 · HL · contact PI
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin$574,328
R01 · FY2018 · HL · contact PI
Training in Translational Research and Entrepreneurship in Pulmonary Vascular Biology$334,656
T32 · FY2018 · HL · contact PI
Administrative Core$156,501
P01 · FY2018 · HL · contact PI
Therapeutic Targeting of Vascular Subphenotypes of Lung Disease$2,700,395
P01 · FY2017 · HL · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$651,399
R01 · FY2017 · HL · contact PI
Nitrite-signaling to modulate the metabolic syndrome and PH in patients with PH-HFpEF$626,746
P01 · FY2017 · HL · contact PI
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin$582,028
R01 · FY2017 · HL · contact PI
Training in Translational Research and Entrepreneurship in Pulmonary Vascular Biology$335,915
T32 · FY2017 · HL · contact PI
Administrative Core$155,584
P01 · FY2017 · HL · contact PI
Translational Pulmonary Vascular Biology$1,944
T32 · FY2017 · HL · contact PI
Therapeutic Targeting of Vascular Subphenotypes of Lung Disease$2,704,375
P01 · FY2016 · HL · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$645,717
R01 · FY2016 · HL · contact PI
Nitrite-signaling to modulate the metabolic syndrome and PH in patients with PH-HFpEF$620,871
P01 · FY2016 · HL · contact PI
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin$595,927
R01 · FY2016 · HL · contact PI
Administrative Core$154,125
P01 · FY2016 · HL · contact PI
Translational Pulmonary Vascular Biology$125,670
T32 · FY2016 · HL · contact PI
Vascular Subphenotypes of Lung Disease$2,459,371
P01 · FY2015 · HL · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$746,695
R01 · FY2015 · HL · contact PI
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin$613,799
R01 · FY2015 · HL · contact PI
Pulmonary vascular-targeted NO therapeutic strategies$447,710
P01 · FY2015 · HL · contact PI
Translational Pulmonary Vascular Biology$188,684
T32 · FY2015 · HL · contact PI
Administrative Core$97,905
P01 · FY2015 · HL · contact PI
Vascular Subphenotypes of Lung Disease$2,477,787
P01 · FY2014 · HL · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$684,147
R01 · FY2014 · HL · contact PI
Translational Training Program in Pulmonary Biology and Medicine$654,104
T32 · FY2014 · HL · contact PI
Pulmonary vascular-targeted NO therapeutic strategies$446,099
P01 · FY2014 · HL · contact PI
Translational Pulmonary Vascular Biology$309,083
T32 · FY2014 · HL · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$100,000
R01 · FY2014 · HL · contact PI
Administrative Core$90,968
P01 · FY2014 · HL · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$49,621
R01 · FY2014 · HL · contact PI
Vascular Subphenotypes of Lung Disease$2,437,938
P01 · FY2013 · HL · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$670,537
R01 · FY2013 · HL · contact PI
Translational Training Program in Pulmonary Biology and Medicine$612,011
T32 · FY2013 · HL · contact PI
Pulmonary vascular-targeted NO therapeutic strategies$432,711
P01 · FY2013 · HL · contact PI
Myoglobin as a Nitrite Reductase that Regulates Hypoxic Cardiac NO Signaling$345,471
R01 · FY2013 · HL · contact PI
Translational Pulmonary Vascular Biology$303,212
T32 · FY2013 · HL · contact PI
Administrative Core$94,624
P01 · FY2013 · HL · contact PI
Vascular Subphenotypes of Lung Disease$2,556,023
P01 · FY2012 · HL · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$672,697
R01 · FY2012 · HL · contact PI
Pulmonary vascular-targeted NO therapeutic strategies$438,774
P01 · FY2012 · HL · contact PI
Myoglobin as a Nitrite Reductase that Regulates Hypoxic Cardiac NO Signaling$363,051
R01 · FY2012 · HL · contact PI
Translational Pulmonary Vascular Biology$149,286
T32 · FY2012 · HL · contact PI
Administrative Core$99,396
P01 · FY2012 · HL · contact PI
Vascular Subphenotypes of Lung Disease$2,588,070
P01 · FY2011 · HL · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$688,267
R01 · FY2011 · HL · contact PI
Pulmonary vascular-targeted NO therapeutic strategies$440,379
P01 · FY2011 · HL · contact PI
Myoglobin as a Nitrite Reductase that Regulates Hypoxic Cardiac NO Signaling$367,978
R01 · FY2011 · HL · contact PI
Administrative Core$108,486
P01 · FY2011 · HL · contact PI
Translational Vascular Biology in Autoimmune Diseases$744,615
P30 · FY2010 · AR · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$695,694
R01 · FY2010 · HL · contact PI
Dietary nitrate activation of PPARgamma improves insulin sensitivity$499,591
RC1 · FY2010 · DK · contact PI
Myoglobin as a Nitrite Reductase that Regulates Hypoxic Cardiac NO Signaling$404,561
R01 · FY2010 · HL · contact PI
Translational Vascular Biology in Autoimmune Diseases$709,037
P30 · FY2009 · AR · contact PI
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide Homeostasis$706,107
R01 · FY2009 · HL · contact PI
Dietary nitrate activation of PPARgamma improves insulin sensitivity$499,589
RC1 · FY2009 · DK · contact PI
Multicenter Trial of NO for Acute Treatment of Sickle Cell Pain Episodes$1,228,440
Z01 · FY2008 · HL · contact PI
Prevalence of PAH in SCD Patients in Nigeria$954,218
Z01 · FY2008 · HL · contact PI
Hemolysis, NO and PAH in Malaria$954,218
Z01 · FY2008 · HL · contact PI
Synergy of Hydroxyurea and Erythropoietin on Fetal Hemoglobin in SCD$635,991
Z01 · FY2008 · HL · contact PI
Prevalence And Prognosis Of Pulmonary Hypertension In Adults With Sickle Cell$87,018
Z01 · FY2008 · CL · contact PI
Blood Studies of Endothelial Function and Systemic Inflammation$32,321
Z01 · FY2008 · CL · contact PI
Systemic Nitrite Infusion and its Effect on Exercise Physiology and Metabolism$31,962
Z01 · FY2008 · HL · contact PI
Nitrite Infusion Studies on Healthy Volunteers$31,962
Z01 · FY2008 · HL · contact PI
Use of Hydroxyurea & L-arginine or Sildenafil in Patients w/Sickle Cell Disease$31,962
Z01 · FY2008 · HL · contact PI
Nitric Oxide For Patients With Sickle Cell Anemia And Pulmonary Hypertension$4,972
Z01 · FY2008 · CL · contact PI
Multicenter Trial of NO for Acute Treatment of Sickle Cell Pain Episodes$821,996
Z01 · FY2007 · HL · contact PI
Synergy of Hydroxyurea and Erythropoietin on Fetal Hemoglobin in SCD$748,968
Z01 · FY2007 · HL · contact PI
Prevalence of PAH in SCD Patients in Nigeria$641,972
Z01 · FY2007 · HL · contact PI
Hemolysis, NO and PAH in Malaria$641,972
Z01 · FY2007 · HL · contact PI
Nitrite Infusion Studies on Healthy Volunteers$213,991
Z01 · FY2007 · HL · contact PI
Systemic Nitrite Infusion and its Effect on Exercise Physiology and Metabolism$213,991
Z01 · FY2007 · HL · contact PI
Use of Hydroxyurea & L-arginine or Sildenafil in Patients w/Sickle Cell Disease$213,991
Z01 · FY2007 · HL · contact PI
Use of Bosentan in Patients with Symptomatic PH Associated with SCD$213,991
Z01 · FY2007 · HL · contact PI
Prevalence And Prognosis Of Pulmonary Hypertension In Adults With Sickle Cell$43,600
Z01 · FY2007 · CL · contact PI
Blood Studies of Endothelial Function and Systemic Inflammation$16,764
Z01 · FY2007 · CL · contact PI
Cardiopulmonary Function Assessment and NO Based Therapies for SCD Pts with PAH$16,612
Z01 · FY2007 · CL · contact PI
Evaluation of Endothelial Function in HIV Associated PAH$10,900
Z01 · FY2007 · CL · contact PI
Nitric Oxide For Patients With Sickle Cell Anemia And Pu$0
Z01 · FY2006 · CL · contact PI
Use of Hydroxyurea & L-arginine or Sildenafil in Patient$0
Z01 · FY2006 · HL · contact PI
Synergy of Hydroxyurea and Erythropoietin on Fetal Hemog$0
Z01 · FY2006 · HL · contact PI
Prevalence of PAH in SCD Patients in Nigeria$0
Z01 · FY2006 · HL · contact PI
Nitrite Infusion Studies on Healthy Volunteers$0
Z01 · FY2006 · HL · contact PI
Multicenter Trial of NO for Acute Treatment of Sickle Ce$0
Z01 · FY2006 · HL · contact PI
Systemic Nitrite Infusion and its Effect on Exercise Phy$0
Z01 · FY2006 · HL · contact PI
Blood Studies of Endothelial Function and Systemic Infla$0
Z01 · FY2006 · CL · contact PI
Prevalence And Prognosis Of Pulmonary Hypertension In Ad$0
Z01 · FY2006 · CL · contact PI
Nitric Oxide For Patients With Sickle Cell Anemia And Pu$0
Z01 · FY2005 · CL
Nitrite Infusion Studies on Healthy Volunteers$0
Z01 · FY2005 · HL
Systemic Nitrite Infusion and its Effect on Exercise Phy$0
Z01 · FY2005 · HL
Multicenter Trial of NO for Acute Treatment of Sickle Ce$0
Z01 · FY2005 · HL
Use of Hydroxyurea &L-arginine or Sildenafil in SCD$0
Z01 · FY2005 · CL
Blood Studies of Endothelial Function and Systemic Infla$0
Z01 · FY2005 · CL
Prevalence And Prognosis Of Pulmonary Hypertension In Ad$0
Z01 · FY2005 · CL
Prevalence And Prognosis Of Pulmonary Hypertension In Ad$0
Z01 · FY2005 · CL
Nitric Oxide: Sickle Cell Anemia/Pulmonary Hypertension$0
Z01 · FY2004 · CL
Hydroxyurea/L-arginine or Sildenafil Sickle Cell Disease$0
Z01 · FY2004 · CL
Blood Studies Endothelial Function/Systemic Inflammation$0
Z01 · FY2004 · CL
Sickle Cell: Risk/Prognosis Of Pulmonary Hypertension$0
Z01 · FY2004 · CL
Prevalence And Prognosis Of Pulmonary Hypertension In Ad$0
Z01 · FY2003 · CL
Hydroxyurea &L-arginine or Sildenafil in Patients w/SCD$0
Z01 · FY2003 · CL
Blood Studies of Endothelial Function /Systemic Inflamma$0
Z01 · FY2003 · CL
Nitric Oxide For Patients With Sickle Cell Anemia And Pu$0
Z01 · FY2003 · CL
Nitric Oxide For Patients With Sickle Cell Anemia And Pu$0
Z01 · FY2002 · CL
Delivery Of NO By Hemoglobin To Improve Blood Flow In Si$0
Z01 · FY2002 · CL
Prevalence And Prognosis Of Pulmonary Hypertension In Ad$0
Z01 · FY2002 · CL
Physiologic Effects Of Inhaled Nitric Oxide, Nitroglycer$0
Z01 · FY2002 · CL
Physiologic Effects Of Inhaled Nitric Oxide, Nitroglycer$0
Z01 · FY2001 · CL
Effects Of Endothelium-derived Versus Hemoglobin-transpo$0
Z01 · FY2001 · CL
Delivery Of NO By Hemoglobin To Improve Blood Flow In Si$0
Z01 · FY2001 · CL
Prevalence And Prognosis Of Pulmonary Hypertension In Ad$0
Z01 · FY2001 · CL
Nitric Oxide For Patients With Sickle Cell Anemia And Pu$0
Z01 · FY2001 · CL
Physiologic Effects of Inhaled Nitric Oxide, Nitroglycerin, and Placebo in Study$0
Z01 · FY2000 · CL